CN110291105B - 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 - Google Patents

导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 Download PDF

Info

Publication number
CN110291105B
CN110291105B CN201880006141.0A CN201880006141A CN110291105B CN 110291105 B CN110291105 B CN 110291105B CN 201880006141 A CN201880006141 A CN 201880006141A CN 110291105 B CN110291105 B CN 110291105B
Authority
CN
China
Prior art keywords
seq
antibody
guide
sequence
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880006141.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110291105A (zh
Inventor
邦雅曼·迪卡鲁热
达维德·戈德施奈德
安娜·玛丽亚·丽塔·雷达维德
邦雅曼·吉贝尔
帕特里克·梅伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
Claude Bernardrian First University
French National Institute Of Health And Medicine
Centre National de la Recherche Scientifique
Netris Pharma SAS
Original Assignee
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
Claude Bernardrian First University
French National Institute Of Health And Medicine
Centre National de la Recherche Scientifique
Netris Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD, Claude Bernardrian First University, French National Institute Of Health And Medicine, Centre National de la Recherche Scientifique, Netris Pharma SAS filed Critical CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
Publication of CN110291105A publication Critical patent/CN110291105A/zh
Application granted granted Critical
Publication of CN110291105B publication Critical patent/CN110291105B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880006141.0A 2017-01-05 2018-01-05 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 Active CN110291105B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305014 2017-01-05
EP17305014.7 2017-01-05
PCT/EP2018/050289 WO2018127570A1 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Publications (2)

Publication Number Publication Date
CN110291105A CN110291105A (zh) 2019-09-27
CN110291105B true CN110291105B (zh) 2024-03-01

Family

ID=57838304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006141.0A Active CN110291105B (zh) 2017-01-05 2018-01-05 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗

Country Status (10)

Country Link
US (2) US12162932B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565837B1 (cg-RX-API-DMAC7.html)
JP (2) JP7211952B2 (cg-RX-API-DMAC7.html)
KR (1) KR102679324B1 (cg-RX-API-DMAC7.html)
CN (1) CN110291105B (cg-RX-API-DMAC7.html)
AU (1) AU2018205730B2 (cg-RX-API-DMAC7.html)
CA (1) CA3048347A1 (cg-RX-API-DMAC7.html)
EA (1) EA039433B1 (cg-RX-API-DMAC7.html)
IL (1) IL267775B1 (cg-RX-API-DMAC7.html)
WO (1) WO2018127570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
MX2024001308A (es) * 2021-07-27 2024-05-23 Netris Pharma Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones.
CA3246346A1 (en) * 2022-03-29 2023-10-05 Netris Pharma NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR
WO2024095723A1 (ja) 2022-11-02 2024-05-10 シチズン・システムズ株式会社 プリンタ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途
WO2015104360A1 (en) * 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2601352T3 (es) 2006-02-28 2017-02-14 Centre National De La Recherche Scientifique (Cnrs) Cribado para compuestos anti-cáncer usando actividad de netrina-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2609430A1 (en) 2010-08-26 2013-07-03 F.Hoffmann-La Roche Ag Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104360A1 (en) * 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody
CN105979966A (zh) * 2014-01-10 2016-09-28 奈特里斯药物公司 新的抗神经诱向因子-1抗体
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途

Also Published As

Publication number Publication date
KR20190101991A (ko) 2019-09-02
EP3565837C0 (en) 2024-04-10
EP3565837B1 (en) 2024-04-10
CA3048347A1 (en) 2018-07-12
JP2022176250A (ja) 2022-11-25
AU2018205730B2 (en) 2024-05-30
EA201991302A1 (ru) 2019-11-29
WO2018127570A1 (en) 2018-07-12
IL267775B1 (en) 2026-06-01
IL267775A (en) 2019-09-26
EP3565837A1 (en) 2019-11-13
US20190315852A1 (en) 2019-10-17
AU2018205730A1 (en) 2019-07-11
JP2020503359A (ja) 2020-01-30
US12162932B2 (en) 2024-12-10
CN110291105A (zh) 2019-09-27
EA039433B1 (ru) 2022-01-27
KR102679324B1 (ko) 2024-06-28
US20250002572A1 (en) 2025-01-02
JP7211952B2 (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
US20210115123A1 (en) Trispecific inhibitors for cancer treatment
CN112513080B (zh) Vista抗原结合分子
JP2023126946A (ja) 抗lag-3抗体、pd-1経路阻害剤および免疫療法剤の組み合わせを含む組成物
JP7754506B2 (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
KR20190022632A (ko) Lag-3 결합 구성원
US20250002572A1 (en) Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
JP2020511481A (ja) 固形及び血液癌の治療のための併用療法
WO2019195452A1 (en) Anti-cd27 antibodies and uses thereof
JP7712496B2 (ja) 抗cd39抗体及びその使用
CN116390755A (zh) 抗pd-1/cd40双特异性抗体及其用途
IL269577A (en) Bispecific anti-PD-L1-anti-TIM-3 antibodies
US20220332818A1 (en) Bispecific antibody targeting pd-1 and tim-3
TWI917473B (zh) Bcma/taci抗原結合分子
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20240190961A1 (en) Combination of anti-garp antibody and immunomodulator
HK40129808A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
HK40070578A (en) Combination of anti-garp antibody and immunoregulator
HK40124330A (en) Anti-cd39 antibodies and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant